Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment

Ilaria Marech; Christian Leporini; Michele Ammendola; Mariangela Porcelli; Cosmo Damiano Gadaleta; Emilio Russo; Giovambattista De Sarro; Girolamo Ranieri

doi:10.1016/j.canlet.2015.07.028

Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment

Ilaria Marech, Christian Leporini, Michele Ammendola, Mariangela Porcelli, Cosmo Damiano Gadaleta, Emilio Russo, Giovambattista De Sarro, Girolamo Ranieri

IRCCS Giovanni Paolo II

Research output: Contribution to journal › Article

Abstract

Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.

Original language	English
Journal	Cancer Letters
DOIs	https://doi.org/10.1016/j.canlet.2015.07.028
Publication status	Accepted/In press - 2015

Keywords

Cancer
Endothelial cells
Novel antiangiogenic therapies
Proangiogenic factors
Tumor angiogenesis

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1016/j.canlet.2015.07.028

Fingerprint Dive into the research topics of 'Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment'. Together they form a unique fingerprint.

Cite this

@article{9743e737d9db45d4bc8e7b0cee3aaba9,

title = "Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment",

abstract = "Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.",

keywords = "Cancer, Endothelial cells, Novel antiangiogenic therapies, Proangiogenic factors, Tumor angiogenesis",

author = "Ilaria Marech and Christian Leporini and Michele Ammendola and Mariangela Porcelli and Gadaleta, {Cosmo Damiano} and Emilio Russo and {De Sarro}, Giovambattista and Girolamo Ranieri",

year = "2015",

doi = "10.1016/j.canlet.2015.07.028",

language = "English",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment

AU - Marech, Ilaria

AU - Leporini, Christian

AU - Ammendola, Michele

AU - Porcelli, Mariangela

AU - Gadaleta, Cosmo Damiano

AU - Russo, Emilio

AU - De Sarro, Giovambattista

AU - Ranieri, Girolamo

PY - 2015

Y1 - 2015

N2 - Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.

AB - Angiogenesis is sustained by classical and non-classical proangiogenic factors (PFs) acting in tumor microenvironment and these factors are also potential targets of antiangiogenic therapies. All PFs induce the overexpression of several signaling pathways that lead to migration and proliferation of endothelial cells contributing to tumor angiogenesis and survival of cancer cells. In this review, we have analyzed each PF with its specific receptor/s and we have summarized the available antiangiogenic drugs (e.g. monoclonal antibodies) targeting these PFs, some of these agents have already been approved, others are currently in development for the treatment of several human malignancies.

KW - Cancer

KW - Endothelial cells

KW - Novel antiangiogenic therapies

KW - Proangiogenic factors

KW - Tumor angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=84939864830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939864830&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2015.07.028

DO - 10.1016/j.canlet.2015.07.028

M3 - Article

AN - SCOPUS:84939864830

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -